Regeneron Pharmaceuticals on Monday announced it is buying 23andMe out of bankruptcy for $256 million – taking with it the company’s extensive trove of genetic samples and data. It will acquire 23andMe’s Personal Genome Service, Total Health and Research Services and its large biobank, including genetic data of more than 15 million customers – raising privacy concerns from individuals who had willingly handed over the samples to completely different owners. All of 23andMe’s genetic testing services will continue uninterrupted, and the deal is expected to close in the third quarter of 2025 pending bankruptcy court and regulatory approvals, Regeneron said....